Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $628M (down 76.1% year over year) with net income of −$6M.
Q1 2026 key financials · XBRL
- Revenue
- $628M
- −76.1% YoY
- Net income
- −$6M
- +74.1% YoY
- Operating margin
- 2.7%
- EPS (diluted)
- −$0.08
- +75.0% YoY
Source: XBRL data from the ACCENDRA HEALTH INC/VA/ (ACH) Q1 2026 10-Q on SEC EDGAR. USD.
ACCENDRA HEALTH INC/VA/ Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $627.8M, down $46.1M or 6.8% YoY
- Cost margin 44.3% vs 47.4% YoY; net loss $6.5M vs $3.8M
- Best line: urology revenue $29.8M, up 5.9%; worst: other revenue $57.4M, down 20.1%
- Cash $336.9M, up $54.9M; operating cash flow $(50.1)M vs $31.5M
- Payor termination reduced revenue $42M; Balance Sheet Optimization Transaction expected in second quarter 2026
Risk Factors
- Risk factors unchanged through March 31, 2026, with no newly added or materially updated risks
- Carried-forward regulatory and compliance risks remain those disclosed in the December 31, 2025 Form 10-K
- Share-repurchase liquidity risk: $89.86 million remained available under the $100 million authorization through February 2027
- Capital-allocation risk: approximately 2.0 million shares repurchased for $10 million since February 26, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCENDRA HEALTH INC/VA/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.